Royalty Pharma (RPRX) Retained Earnings (2019 - 2026)

Royalty Pharma has disclosed Retained Earnings across 8 years of filings, most recently posting $4.4 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 6.02% year-over-year to $4.4 billion; the TTM figure through Jun 2026 stood at $4.4 billion (up 6.02% YoY), while the FY2025 annual figure was $4.1 billion, changed 0.48% from the prior year.
• Retained Earnings came in at $4.4 billion for Q2 2026 at Royalty Pharma, roughly flat from $4.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.4 billion in Q1 2026 to a low of $3.5 billion in Q1 2022.
• Average Retained Earnings over 5 years is $4.0 billion, with a median of $4.1 billion recorded in 2024.
• Year-over-year, Retained Earnings advanced 20.88% in 2022 and gained 0.12% in 2025.
• Over 5 years, Retained Earnings stood at $3.7 billion in 2022, then climbed by 9.42% to $4.0 billion in 2023, then gained by 2.29% to $4.1 billion in 2024, then grew by 0.48% to $4.1 billion in 2025, then rose by 6.14% to $4.4 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $4.4 billion in Q2 2026, $4.4 billion in Q1 2026, and $4.1 billion in Q4 2025.